Literature DB >> 32667865

Let-7d-5p suppresses inflammatory response in neonatal rats with necrotizing enterocolitis via LGALS3-mediated TLR4/NF-κB signaling pathway.

Liqun Sun1, Meihua Sun1, Ke Ma1, Jiangtao Liu1.   

Abstract

Necrotizing enterocolitis (NEC) is an acute intestinal condition accounting for severe mortality and morbidity in preterm infants. This study aimed to identify the possible roles of let-7d-5p in neonatal rats with NEC. The differentially expressed genes (DEGs) related to NEC were initially screened in silico. After establishment of NEC rat models, measurement of the expression of let-7d-5p, galectin-3 (LGALS3), Toll-like receptor 4 (TLR4), and nuclear factor-κB (NF-κB) as well as proinflammatory cytokines (TNF-α, IL-1β, and IL-6) was conducted. The interaction between let-7d-5p and LGALS3 or argonaute-2 (AGO2) was identified. Gain- and loss-of-function approaches were then performed in an attempt to investigate the regulatory roles of let-7d-5p and LGALS3 in inflammation and cell apoptosis in NEC neonatal rats. Let-7d-5p was poorly expressed, whereas LGALS3, TLR4, and NF-κB were highly expressed, in the intestinal tissues of NEC rats. Overexpression of let-7d-5p resulted in decreased levels of proinflammatory factors in the intestinal tissues of NEC rats. Through sequential experimentation, let-7d-5p was identified to target LGALS3 and bind to AGO2. In addition, LGALS3 silencing or LPS treatment blocked the TLR4/NF-κB signaling pathway, thereby suppressing intestinal epithelial cell apoptosis and inflammation in NEC. Collectively, let-7d-5p might exercise its inhibitory properties in the inflammatory response and intestinal epithelial cell apoptosis in NEC neonatal rats via inactivation of the LGALS3-dependent TLR4/NF-κB signaling pathway.

Entities:  

Keywords:  LGALS3; NF-κB; Toll-like receptor 4; let-7d-5p; necrotizing enterocolitis

Mesh:

Substances:

Year:  2020        PMID: 32667865     DOI: 10.1152/ajpcell.00571.2019

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  7 in total

1.  Human Breast Milk-Derived Exosomal miR-148a-3p Protects Against Necrotizing Enterocolitis by Regulating p53 and Sirtuin 1.

Authors:  Miao-Miao Guo; Kun Zhang; Jia-Hui Zhang
Journal:  Inflammation       Date:  2022-01-29       Impact factor: 4.092

2.  MiRNA Let-7a and Let-7d Are Induced by Globotriaosylceramide via NF-kB Activation in Fabry Disease.

Authors:  Nadine Maier; Constantin Gatterer; Patrick Haider; Manuel Salzmann; Christoph Kaun; Walter S Speidl; Gere Sunder-Plassmann; Bruno K Podesser; Johann Wojta; Senta Graf; Max Lenz; Philipp J Hohensinner
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

Review 3.  Galectin-8, cytokines, and the storm.

Authors:  Yehiel Zick
Journal:  Biochem Soc Trans       Date:  2022-02-28       Impact factor: 4.919

4.  Intratumoral administration of the antisecretory peptide AF16 cures murine gliomas and modulates macrophage functions.

Authors:  Jan Kopecky; Julio Enríquez Pérez; Håkan Eriksson; Edward Visse; Peter Siesjö; Anna Darabi
Journal:  Sci Rep       Date:  2022-03-17       Impact factor: 4.379

Review 5.  Role of omega-3 polyunsaturated fatty acids, citrus pectin, and milk-derived exosomes on intestinal barrier integrity and immunity in animals.

Authors:  Tamil Selvi Sundaram; Carlotta Giromini; Raffaella Rebucci; Juraj Pistl; Mangesh Bhide; Antonella Baldi
Journal:  J Anim Sci Biotechnol       Date:  2022-04-11

6.  Knockdown of TRPM7 attenuates apoptosis and inflammation in neonatal necrotizing enterocolitis model cell IEC-6 via modulating TLR4/NF-κB and MEK/ERK pathways.

Authors:  Lu An; Juan Li; Bing Liu; Junpeng Hui; Qiang Zhang; Xin Zhang; Qi Wang
Journal:  Iran J Basic Med Sci       Date:  2022-08       Impact factor: 2.532

Review 7.  Roles of exosomes and exosome-derived miRNAs in pulmonary fibrosis.

Authors:  Yongfeng Yang; Hong Huang; Yi Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.